Applications of Montelukast in Industrial Manufacturing

Montelukast, a leukotriene receptor antagonist, serves as a specialized active ingredient across advanced pharmaceutical manufacturing. As a high-purity API, it finds utility where strict regulatory compliance, precise formulation, and validated process integration drive downstream product quality and safety. Our manufacturing expertise supports a range of sectors requiring compliant, reproducible Montelukast inputs to achieve targeted performance in high-value dosage forms.

1. Solid Oral Antiasthmatic Drug Formulations

Montelukast plays a crucial role in the production of solid oral dosage forms for allergy and asthma management, notably coated tablets and chewable tablets, where consistent bioavailability and stability are essential. This application requires the pure compound to be directly incorporated into the blending stage prior to granulation, ensuring batch uniformity and regulated dose delivery. Final products target both adult and pediatric patient populations, and each production run demands rigorous testing and documentation to satisfy international pharmaceutical regulations.

Industry compliance standards

• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur.)
• ChP (Chinese Pharmacopoeia)
• Good Manufacturing Practice (GMP) Guidelines (ICH Q7, WHO GMP)

Typical usage ratio

• Final API content typically 4–10 mg per tablet; added at up to 1–2% w/w of batch granulation mass, adjusted to meet target dosage and tablet size specifications.

Downstream process integration

• Montelukast is dispensed into the blending step prior to wet granulation for tablets or directly into the dry mix for chewable formulations, followed by tableting and film-coating.

Final product types

• Paediatric chewable tablets
• Film-coated tablets for adult use
• Pediatric dispersible tablets

2. Sachet and Granule Pharmaceutical Preparations

In pediatric and geriatric medicine, Montelukast is widely used in granule and sachet dosage forms enabling flexible, age-appropriate administration. Addressing both patient compliance and stability, manufacturers must control granule homogeneity and dissolution profiles. The raw material integrates at the microencapsulation or blending stage, preceding single-dose sachet filling and sterile packaging. Formulation and process must satisfy variations in regulatory requirements for combination products containing flavoring agents.

Industry compliance standards

• European Medicines Agency (EMA) Pediatric Investigation Plan (PIP)
• US FDA 21 CFR 210/211 (for finished pharmaceuticals)
• Ph. Eur. 5.2.8: Uniformity of dosage units
• GMP (Global Compliance: PIC/S, US, EU)

Typical usage ratio

• Typically 4 mg Montelukast per sachet; incorporated at 0.5–1.5% w/w of total granule blend, adjusted per sachet weight and excipient profile.

Downstream process integration

• Montelukast enters the dry blend phase or is coated onto inert pellets, then the granules pass through sieving, flavor mixing, and high-speed sachet filling before QA/QC and packaging.

Final product types

• Pediatric oral granules (sachets)
• Instant oral powder for solution

3. Oral Liquid Suspension Manufacturing

This non-solid dosage application caters to patients with swallowing difficulties and requires the bulk Montelukast to disperse uniformly within vehicle suspensions without sedimentation. The material is dissolved or finely dispersed in the syrup base at the wet mixing stage, often in the presence of stabilizing agents. Strict process controls are imposed to ensure dissolution, homogeneity, and microbiological safety. Regulatory reviews demand repeatable validation dossiers and routine in-process monitoring throughout jet-milling, mixing, and aseptic filling.

Industry compliance standards

• WHO Model Formulary guidelines for pediatric liquids
• US Pharmacopeia <795> Pharmaceutical Compounding—Nonsterile Preparations
• ICH Q6A: Specifications for New Drug Substances and Products
• FDA cGMP for liquid dosage forms

Typical usage ratio

• Standard commercial suspensions contain Montelukast at 4–10 mg/5mL; added at 0.08–0.18% w/v based on bottle fill volume and suspension type.

Downstream process integration

• Montelukast is micronized and dispersed during the aqueous phase mixing immediately prior to homogenization, then emulsified or suspended, and filled under inert gas for microbiological protection.

Final product types

• Pediatric oral suspensions (bottled)
• Unit-dose liquid sticks or sachets

4. Combination Therapy Tablet Production

In certain regulated markets, Montelukast is formulated in fixed-dose tablet combinations with other active compounds such as antihistamines (e.g., desloratadine) to address multifactorial respiratory and allergic disorders. Manufacturers require matched dissolution and stability kinetics in multilayer or coated tablets. The raw API is separately blended and then compressed with synergistic actives using compartmentalized press tooling and multi-stage blending to maintain both ingredient integrity and regulatory-mandated compositional disclosure.

Industry compliance standards

• US FDA Orange Book Listed Drug Products
• EMA fixed combination guideline (EMA/CHMP/158268/2017)
• Ph. Eur. 2.9.3: Dissolution Testing
• ICH Q3A/B: Impurities in New Drug Substances/Products

Typical usage ratio

• Montelukast content kept within 4–10 mg per tablet, typically 0.8–1.6% w/w for total batch, depending on combined actives’ concentrations and regulatory monograph limits.

Downstream process integration

• Montelukast is introduced as an isolated sub-batch in the blending stage, followed by sequential compression or layer-by-layer assembly, with final coating and cross-contamination risk controls.

Final product types

• Fixed-dose combination tablets (Montelukast-antihistamine)
• Polypill formulations for allergy/respiratory disorders